Investigational diabetes drug appears to improve insulin sensitivity without side effects
Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.
"Current diabetes medications activate a receptor that improves insulin sensitivity, but unfortunately also contributes to side effects that make some people discontinue the medication, contributing to other health problems," says principal investigator Brian N. Finck, PhD. "So even though these drugs are effective, we'd really like to find new insulin-sensitizing therapies that would avoid activating the same receptor."
Finck, a research assistant professor of medicine in the Division of Geriatrics and Nutritional Science, worked with colleagues at the University of Michigan and at the drug discovery company Metabolic Solutions Development Co., LLC. The scientists studied one of the company's investigational drugs, MSD-0602, focusing on its effects in obese mice.
The drug improved blood glucose levels and insulin tolerance in the mice, as did the two diabetes drugs that already are on the market: rosiglitazone (Avandia) and pioglitazone (Actos). All three medications appeared to be about equally effective, but MSD-0602 didn't bind to and activate a receptor in cells called PPARγ. Rather, the investigational drug clings to the mitochondria, part of the cell that produces energy.
"The drug altered the cell's ability to generate energy," Finck says. "And it also seems to have an anti-inflammatory role in the cell. We also found that the drug improved insulin sensitivity in many different kinds of cells including muscle, fat and liver cells."
Next, he and his colleagues will attempt to identify proteins that bind to the mitochondrial membrane. Future therapies then could be developed specifically to bind to those proteins while avoiding activation of the PPARγ pathway.
Investigational diabetes drug appears to improve insulin sensitivity without side effects: Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.
Ref : http://www.jbc.org/content/early/2012/05/23/jbc.M112.363960.full.pdf
Labels: antidiabetic, MSDC-0602, rosiglitazone (Avandia) and pioglitazone, thiadiazolidindiones
Drug Combo Tackling Solid Tumors
Takeda announces updated results from orteronel ph...
Antisense Pharma presents data from trabedersen Ph...
Ancient berry could protect against diabetic retin...
Dapivirine Phase III trial now underway in Africa ...
Investigational diabetes drug appears to improve i...
Cyclacel Presents New Phase 2 Data of Sapacitabine...
For advanced prostate cancer, new drug slows disea...
RA Study Misses Primary Endpoint (CH-4051)...
Thioridazine drug successfully kills human cancer ...
Onyx receives FDA approval for Kyprolis to treat m...
FDA approves Cipher's Absorica to treat severe rec...
APD421 Reduces Nausea, Vomiting....
FDA accepts NDA filing for KYNAMRO to treat HoFH.....
Diabetes Drug Could Be a Promising Therapy for Tra...
USPTO issues patent to MicuRx's MRX-I antibacteria...
Azithromycin can be effective treatment option for...
Positive Results from Tesetaxel Study
Tivantinib Meets Study Endpoint
New anti-cancer drug developed
Successful Completion Of Proof-of-concept Clinical...
Achillion Announces Additional Proof-of-Concept Da...
Heparin-like compounds inhibit breast cancer metas...
NSAIDs and Cardiovascular Risk Explained, Accordin...
A high-throughput drug screen for Entamoeba histol...
Study shows how a drug-lead compound suppresses tu...
Scientists unravel action mechanism of castor oil
New Blood Thinner May Lower Chances of Clots in Hi...
Cobiprostone shows promise against NSAID-induced g...
Pernix Therapeutics introduces Omeclamox-Pak® for ...